Work

Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.4553

Authors: Elizabeth R. Plimack, Hans J. Hammers, Brian I. Rini, David F. McDermott, Bruce Redman, Timothy Kuzel, Michael Roger Harrison, Ulka N. Vaishampayan, Harry A. Drabkin, Saby George, Theodore F. Logan, Kim Allyson Margolin, Li-an Xu, Ian Waxman, Robert Motzer

Institutions: Fox Chase Cancer Center, Sidney Kimmel Comprehensive Cancer Center, Cleveland Clinic, Beth Israel Deaconess Medical Center, U-M Rogel Cancer Center, Northwestern University, Duke Medical Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Medical University of South Carolina, Roswell Park Comprehensive Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Seattle Cancer Care Alliance, Bristol-Myers Squibb (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2595956476

Cites:

Cited by: 12

Related to: 10